Cotización Panacea Acquisition - NUVB

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Último Precio

2.675

Postura de Compra

Postura de Venta

Volume Operado de la Acción

1,653,585

2.545 Rango del Día 2.73

1.21 Rango de 52 semanas 4.1598

Capitalización de Mercado [m]

900.315M

Precio Anterior

2.58

Precio de Apertura

2.63

Hora

2.675

Última hora de negociación

13:28:55

Volumen financiero

US$ 4,364,306

Precio Promedio Ponderado

2.6393

Volumen promedio (3 m)

1,778,902

Acciones en circulación

336,566,525

Rendimiento del Dividendo

Ratio Precio/Utilidad

-11.90

Beneficio por acción (BPA)

-0.23

turnover

Beneficio neto

-75.8M

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of t... Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

ecor1cap.com

Sede

Wilmington, Delaware, USA

Fundado

Panacea Acquisition Corp is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker NUVB. The last closing price for Panacea Acquisition was US$2.58. Over the last year, Panacea Acquisition shares have traded in a share price range of US$ 1.21 to US$ 4.1598.

Panacea Acquisition currently has 336,566,525 shares in issue. The market capitalisation of Panacea Acquisition is US$868.34 million. Panacea Acquisition has a price to earnings ratio (PE ratio) of -11.90.

Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024

Tumors shrank in 89% of taletrectinib-treated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who were tyrosine kinase inhibitor (TKI)-naïve and 56% of those who...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.285	-9.62837837838	2.96	2.98	2.435	2356477	2.63700194	CS
4	0.345	14.8068669528	2.33	3.08	2.18	2198064	2.61968034	CS
12	-0.585	-17.9447852761	3.26	3.3986	2	1778902	2.61401543	CS
26	-0.785	-22.6878612717	3.46	3.97	2	1698135	2.84813717	CS
52	1.345	101.127819549	1.33	4.1598	1.21	1431407	2.70095137	CS
156	-6.555	-71.0184182015	9.23	10.45	0.95	1058085	3.1151654	CS
260	-7.325	-73.25	10	15.23	0.95	998995	4.35143193	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
CTVInnovid Corp	US$ 3.015 (86.11%)	50.79M
SNOWSnowflake Inc	US$ 170.7193 (32.22%)	46.05M
SRFMSurf Air Mobility Inc	US$ 2.7041 (31.91%)	622.38k
ODVOsisko Development Corporation	US$ 1.94 (31.08%)	1.72M
VATEINNOVATE Corp	US$ 4.76 (22.37%)	79.76k
CATOCato Corp	US$ 4.95 (-18.59%)	157.02k
KLCKindercare Learning Companies Inc	US$ 19.58 (-14.12%)	1.28M
CLCOCool Company LTD	US$ 9.39 (-11.75%)	1.84M
CPACopa Holdings SA	US$ 93.95 (-11.21%)	897.15k
DNMRDanimer Scientific Inc	US$ 5.0813 (-11.01%)	70.16k
CTVInnovid Corp	US$ 3.015 (86.11%)	50.79M
PLTRPalantir Technologies Inc	US$ 61.53 (-0.95%)	46.26M
SNOWSnowflake Inc	US$ 170.7193 (32.22%)	46.05M
NIONIO Inc	US$ 4.70 (1.08%)	41.9M
IONQIonQ Inc	US$ 33.01 (14.38%)	34.21M